

SPECIAL FEATURES

Highlights of This Issue 6885

CCR Translations

6887 Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats

Linghua Wang and Jaffer A. Ajani

See related articles, p. 7024 and p. 7035

6890 Today's Special on the Anticancer Menu: Immunomodulation by Antifolates

Aitziber Buque, Lorenzo Galluzzi, and Noelia Casares

See related article, p. 7175

6893 ctDNA in Gastric and Gastroesophageal Cancer: Prognostic, Predictive, or Preliminary?

Alexander M. Frankell and Elizabeth C. Smyth

See related article, p. 7098

6896 Class(y) Dissection of BRAF Heterogeneity: Beyond Non-V600

Elisa Fontana and Nicola Valeri

See related article, p. 7089

Reviews

6899 Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies

Christine M. Parseghian, Stefania Napolitano,

Jonathan M. Loree, and Scott Kopetz

6909 Use of Circulating Tumor DNA for Cancer Immunotherapy

Alexandra Snyder, Michael P. Morrissey, and

Matthew D. Hellmann

Perspectives

6916 The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

Himisha Beltran, Andrew Hruszkewycz, Howard I. Scher, Jeffrey Hildesheim, Jennifer Isaacs, Evan Y. Yu, Kathleen Kelly, Daniel Lin, Adam Dicker, Julia Arnold, Toby Hecht, Max Wicha, Rosalie Sears, David Rowley, Richard White, James L. Gulley, John Lee, Maria Diaz Meco, Eric J. Small, Michael Shen, Karen Knudsen, David W. Goodrich, Tamara Lotan, Amina Zoubeidi, Charles L. Sawyers, Charles M. Rudin, Massimo Loda, Timothy Thompson, Mark A. Rubin, Abdul Tawab-Amiri, William Dahut, and Peter S. Nelson

6925 Transforming the Early Drug Development Paradigm at the National Cancer Institute: The Formation of NCI's Experimental Therapeutics Clinical Trials Network (ETCTN)

Holly A. Massett, Grace Mishkin, Jeffrey A. Moscow, Amy Gravell, Michael Stekete, Martha Kruhm, Sae H. Han, Barbara Barry, Michael Montello, James Zwiebel, Jeffrey S. Abrams, James H. Doroshow, and S. Percy Ivy

CLINICAL TRIAL BRIEF REPORT

6932 Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma

Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, Ted A. Gooley, Darrell R. Fisher, Leona A. Holmberg, Robert S. Miyaoka, Brenda M. Sandmaier, Damian J. Green, and Ajay K. Gopal

CLINICAL TRIALS: TARGETED THERAPY

6939 Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist ¹⁷⁷Lu-Satoreotide Tetraxetan

Diane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A. O'Donoghue, Simone Krebs, Kevin D. Staton, Serge K. Lyashchenko, Jason S. Lewis, Nitya Raj, Mithat Gönen, Christian Lohrmann, Lisa Bodei, and Wolfgang A. Weber

6948 Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma

Reena P. Thomas, Seema Nagpal, Michael Iv, Scott G. Soltys, Sophie Bertrand, Judith S. Pelpola, Robyn Ball, Jaden Yang, Vandana Sundaram, Jonathan Lavezo, Donald Born, Hannes Vogel, J. Martin Brown, and Lawrence D. Recht

6958 Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study



Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, and David P. Carbone

Table of Contents

- 6967** Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
Li Li, Liyan Jiang, Yubo Wang, Yizhuo Zhao, Xiao-Ju Zhang, Guoming Wu, Xiangdong Zhou, Jianguo Sun, Jun Bai, Biyong Ren, Kun Tian, Zhi Xu, Hua-liang Xiao, Qi Zhou, Rui Han, Hengyi Chen, Haidong Wang, Zhenzhou Yang, Chan Gao, Shangli Cai, and Yong He

- 6976** Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes
Valeria Santini, David Valcárcel, Uwe Platzbecker, Rami S. Komrokji, Ann L. Cleverly, Michael M. Lahn, Jan Janssen, Yumin Zhao, Alan Chiang, Aristoteles Giagounidis, Susan C. Guba, Ivelina Gueorguieva, Alicia C. Girvan, Mariana da Silva Ferreira, Tushar D. Bhagat, Kith Pradhan, Ulrich Steidl, Ashwin Sridharan, Britta Will, and Amit Verma


- 6986** A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid, Jay M. Feingold, Kirit M. Ardeshta, Melhem Solh, Leonard T. Hefner, David Ungar, Shui He, Joseph Boni, Karin Havenith, and Owen A. O'Connor


CLINICAL TRIALS: IMMUNOTHERAPY

- 6995** Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Zi-Xun Yan, Li Li, Wen Wang, Bin-Shen OuYang, Shu Cheng, Li Wang, Wen Wu, Peng-Peng Xu, Muharrem Muftuoglu, Ming Hao, Su Yang, Mu-Chen Zhang, Zhong Zheng, James Li, and Wei-Li Zhao
- 7004** A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
Joseph M. Tuscano, Emanuel Maverakis, Susan Groshen, Denice Tsao-Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, and Edward M. Newman

- 7014** Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer
Christian Lohrmann, Eileen M. O'Reilly, Joseph A. O'Donoghue, Neeta Pandit-Taskar, Jorge A. Carrasquillo, Serge K. Lyashchenko, Shutian Ruan, Rebecca Teng, Wolfgang Scholz, Paul W. Maffuid, Jason S. Lewis, and Wolfgang A. Weber

PRECISION MEDICINE AND IMAGING

- 7024** Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade 
Andrew Georgiadis, Jennifer N. Durham, Laurel A. Keefer, Bjarne R. Bartlett, Magdalena Zielonka, Derek Murphy, James R. White, Steve Lu, Ellen L. Verner, Finey Ruan, David Riley, Robert A. Anders, Erika Gedvilaite, Sam Angiuoli, Siân Jones, Victor E. Velculescu, Dung T. Le, Luis A. Diaz Jr, and Mark Sausen
See related commentary, p. 6887

- 7035** Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel 
Jason Willis, Martina I. Lefterova, Alexander Artyomenko, Pashtoon Murtaza Kasi, Yoshiaki Nakamura, Kabir Mody, Daniel V.T. Catenacci, Marwan Fakhri, Catalin Barbacioru, Jing Zhao, Marcin Sikora, Stephen R. Fairclough, Hyuk Lee, Kyoung-Mee Kim, Seung Tae Kim, Jinchul Kim, Danielle Gavino, Manuel Benavides, Nir Peled, Timmy Nguyen, Mike Cusnir, Ramez N. Eskander, Georges Azzi, Takayuki Yoshino, Kimberly C. Banks, Victoria M. Raymond, Richard B. Lanman, Darya I. Chudova, AmirAli Talasaz, Scott Kopetz, Jeeyun Lee, and Justin I. Odegaard
See related commentary, p. 6887

- 7046** Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Maria Ormhøj, Irene Scarfo, Maria L. Cabral, Stefanie R. Bailey, Selena J. Lorrey, Amanda A. Bouffard, Ana P. Castano, Rebecca C. Larson, Lauren S. Riley, Andrea Schmidts, Bryan D. Choi, Rikke S. Andersen, Oriane Cédile, Charlotte G. Nyvold, Jacob H. Christensen, Morten F. Gjerstorff, Henrik J. Ditzel, David M. Weinstock, Torben Barington, Matthew J. Frigault, and Marcela V. Maus

- 7058** Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Kezhong Chen, Heng Zhao, Yanbin Shi, Fan Yang, Lien Tu Wang, Guannan Kang, Yuntao Nie, and Jun Wang

Table of Contents

7068 Individual Assignment of Adult Diffuse Gliomas into the EM/PM Molecular Subtypes Using a TaqMan Low-Density Array
Jiuyi Li, Yang Xue, Anna Wenger, Yingyu Sun, Zheng Wang, Chuanbao Zhang, Yunqiu Zhang, Boglarka Fekete, Bertil Rydenhag, Asgeir Store Jakola, Tao Jiang, Helena Carén, and Xiaolong Fan

7078 Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer
Loren K. Mell, Huanjie Shen, Phuc Felix Nguyen-Tân, David I. Rosenthal, Kaveh Zakeri, Lucas K. Vitzthum, Steven J. Frank, Peter B. Schiff, Andy M. Trotti III, James A. Bonner, Christopher U. Jones, Sue S. Yom, Wade L. Thorstad, Stuart J. Wong, George Shenouda, John A. Ridge, Qiang E. Zhang, and Quynh-Thu Le

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

7089 Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna R. Parikh, Hideaki Bando, Emily E. Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire N. Thant, Elisa de Stanchina, Neal Rosen, Ryan B. Corcoran, Takayuki Yoshino, Zhan Yao, and Hiromichi Ebi
See related commentary, p. 6896

7098 Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma
Steven B. Maron, Leah M. Chase, Samantha Lomnicki, Sara Kochanny, Kelly L. Moore, Smita S. Joshi, Stacie Landron, Julie Johnson, Lesli A. Kiedrowski, Rebecca J. Nagy, Richard B. Lanman, Seung Tae Kim, Jeeyun Lee, and Daniel V.T. Catenacci
See related commentary, p. 6893

7113 Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Jason C. Chang, Deepu Alex, Matthew Bott, Kay See Tan, Venkatraman Seshan, Andrew Golden, Jennifer L. Sauter, Darren J. Buonocore, Chad M. Vanderbilt, Sounak Gupta, Patrice Desmeules, Francis M. Bodd, Gregory J. Riely, Valerie W. Rusch, David R. Jones, Maria E. Arcila, William D. Travis, Marc Ladanyi, and Natasha Rekhtman

7126 NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced *In Vivo* Persistence and Antitumor Activity against Neuroblastoma
Xin Xu, Wei Huang, Andras Heczey, Daofeng Liu, Linjie Guo, Michael Wood, Jingling Jin, Amy N. Courtney, Bin Liu, Erica J. Di Pierro, John Hicks, Gabriel A. Barragan, Ho Ngai, Yuhui Chen, Barbara Savoldo, Gianpietro Dotti, and Leonid S. Metelitsa

7139 BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer
Louise Walsh, Kathryn E. Haley, Bruce Moran, Brian Mooney, Finbarr Tarrant, Stephen F. Madden, Alessandra Di Grande, Yue Fan, Sudipto Das, Oscar M. Rueda, Catriona M. Dowling, Damir Varešlija, Suet-Feung Chin, Sabine Linn, Leonie S. Young, Karin Jirstrom, John P. Crown, Rene Bernards, Carlos Caldas, William M. Gallagher, Darran P. O'Connor, and Triona Ní Chonghaile

7151 A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization
Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai, Kenji Hirotani, Yusuke Ogitani, Akiko Zembutsu, Manabu Abe, Yuki Kaneda, Naoyuki Maeda, Yoshinobu Shiose, Takuma Iguchi, Tomomichi Ishizaka, Tsuyoshi Karibe, Ichiro Hayakawa, Koji Morita, Takashi Nakada, Taisei Nomura, Kenichi Wakita, Takashi Kagari, Yuki Abe, Masato Murakami, Suguru Ueno, and Toshinori Agatsuma

7162 Bioactivation of Napabucasin Triggers Reactive Oxygen Species-Mediated Cancer Cell Death
Fieke E.M. Froeling, Manojit Mosur Swamynathan, Astrid Deschènes, Iok In Christine Chio, Erin Brosnan, Melissa A. Yao, Priya Alagesan, Matthew Lucito, Juying Li, An-Yun Chang, Lloyd C. Trotman, Pascal Belleau, Youngkyu Park, Harry A. Rogoff, James D. Watson, and David A. Tuveson

7175 The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
David A. Schaer, Sandaruwan Geeganage, Nelusha Amaladas, Zhao Hai Lu, Erik R. Rasmussen, Andreas Sonyi, Darin Chin, Andrew Capen, Yanxia Li, Catalina M. Meyer, Bonita D. Jones, Xiaodong Huang, Shuang Luo, Carmine Carpenito, Kenneth D. Roth, Alexander Nikolayev, Bo Tan, Manisha Brahmachary, Krishna Chodavarapu, Frank C. Dorsey, Jason R. Manro, Thompson N. Doman, Gregory P. Donoho, David Surguladze, Gerald E. Hall, Michael Kalos, and Ruslan D. Novosiadly
See related commentary, p. 6890

7189 Therapeutic Targeting of TGF β Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Alexandros Papachristodoulou, Manuela Silgner, Michael Weller, Hannah Schneider, Kathy Hasenbach, Michel Janicot, and Patrick Roth

7202 Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Victoria E. Wang, Jenny Y. Xue, Dennie T. Frederick, Yi Cao, Eva Lin, Catherine Wilson, Anatoly Urisman, David P. Carbone, Keith T. Flaherty, Rene Bernards, Piro Lito, Jeff Settleman, and Frank McCormick



Table of Contents

7218 NKG2D Controls Natural Reactivity of γ 9V δ 2 T Lymphocytes against Mesenchymal Glioblastoma Cells

Cynthia Chauvin, Noémie Joalland, Jeanne Perroteau, Ulrich Jarry, Laura Lafrance, Catherine Willem, Christelle Retière, Lisa Oliver, Catherine Gratas, Laetitia Gautreau-Rolland, Xavier Saulquin, François M. Vallette, Henri Vié, Emmanuel Scotet, and Claire Pecqueur

7229 Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression

Yirui Gui, Adriana Aguilar-Mahecha, Urszula Krzemien, Abdel Hosein, Marguerite Buchanan, Josiane Lafleur, Michael Pollak, Cristiano Ferrario, and Mark Basik

7243 Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment

Ren Luo, Elke Firat, Simone Gaedicke, Elena Guffart, Tsubasa Watanabe, and Gabriele Niedermann

7256 Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy


Reinout H. de Roest, Steven W. Mes, Jos B. Poell, Arjen Brink, Mark A. van de Wiel, Elisabeth Bloemena, Elena Thai, Tito Poli, C. René Leemans, and Ruud H. Brakenhoff

 AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The image shows a lung adenocarcinoma with solid growth pattern. By comprehensive next-generation sequencing (NGS), this tumor had an identical genomic profile to a previously resected adenocarcinoma with entirely different, better-differentiated histologic features. This illustrates histologic progression of lung adenocarcinoma during metastasis, and the utility of NGS in clinical practice for confirming clonally related tumors despite histologic differences. For details, see the article by Chang and colleagues on page 7113 of this issue.



Clinical Cancer Research

25 (23)

Clin Cancer Res 2019;25:6885-7265.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/25/23>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/25/23>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.